|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1,970 DKK | +0.79% |
|
-2.96% | -8.58% |
| Apr. 16 | Genmab, Johnson & Johnson Logs Higher Q1 Sales for Blood Cancer Drug | MT |
| Apr. 16 | Genmab A/S Announces DARZALEX Sales Results for the First Quarter of 2024 | CI |
Antibody-drug conjugates, or ADCs, are manufactured antibodies that are administered to patients intravenously designed to deliver drugs to tumors. "Genmab Strengthens Oncology Portfolio With $1.8 Bln Acquisition of ProfoundBio," at 0753 GMT, incorrectly said that ADCs are designed to use the body's own antibodies to deliver drugs to tumors.
(END) Dow Jones Newswires
04-03-24 0904ET
| 1st Jan change | Capi. | |
|---|---|---|
| -8.58% | 18.15B | |
| -2.63% | 103B | |
| +1.75% | 95.28B | |
| +1.46% | 22.15B | |
| -15.69% | 21.02B | |
| -38.74% | 16.73B | |
| -12.78% | 16.05B | |
| +5.39% | 13.68B | |
| +34.29% | 12.17B | |
| -23.97% | 8.24B |
GENMAB A/S 
